Progress of anticholinergic drugs in the treatment of childhood asthma
10.3760/cma.j.issn.1673-4408.2020.08.011
- VernacularTitle:抗胆碱能药物在儿童哮喘治疗中的研究进展
- Author:
Zhenli ZHU
1
;
Yaoyao LING
;
Yongsheng XU
Author Information
1. 天津医科大学研究生院 300070
- From:
International Journal of Pediatrics
2020;47(8):561-564
- CountryChina
- Language:Chinese
-
Abstract:
Anticholinergic drugs play an important role as bronchodilators in the treatment of obstructive airway diseases, including chronic obstructive pulmonary disease and asthma.Anticholinergic drugs are divided into short-acting muscarinic antagonists(SAMA)and long-acting muscarinic antagonists(LAMA). Ipratropium bromide is a commonly used SAMA in pediatrics and is administered by inhalation.The combination of ipratropium bromide and β 2 receptor agonist can control the acute attack of asthma patients of different ages and degrees.Tiotropium bromide is not only LAMA, but also a long-acting bronchodilator, which selectively and competitively binds to M1, M2, and M3 receptors.Tiotropium bromide can reduce Th2 cytokines and airway inflammation, reduce airway hyperresponsiveness, and inhibit airway remodeling.This article reviews the recent progress of anticholinergic drugs in the treatment of childhood asthma.
